Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation-Reference-Cited by-同舟云学术

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Published:2021-02 Issue:2 Volume:11 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Derman Benjamin A.^ORCID,Stefka Andrew T.^ORCID,Jiang Ken,McIver Amanda,Kubicki Tadeusz^ORCID,Jasielec Jagoda K.,Jakubowiak Andrzej J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-021-00418-2.pdf

Reference15 articles.

1. Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456–2464 (2018).

2. Moreau, P. et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J. Clin. Oncol. 35, 2911–2918 (2017).

3. Zajec, M. et al. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin. Chem. 66, 421–433 (2020).

4. Murray, D. L. et al. Laboratory persistence and clinical progression of small monoclonal abnormalities. Am. J. Clin. Pathol. 138, 609–613 (2012).

5. Barnidge, D. R. et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J. Proteome Res. 13, 1419–1427 (2014).

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future;Blood Reviews;2024-09

2. Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma;Blood;2024-08-29

3. Measurable Residual Disease and Decision-Making in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Endogenous monoclonal immunoglobulins analyzed using the EXENT® solution and LC-MS;Journal of Mass Spectrometry and Advances in the Clinical Lab;2024-04

5. AL amyloidosis response: a move in the “light” direction;Blood;2024-03-28